MBX Biosciences Past Earnings Performance
Past criteria checks 0/6
MBX Biosciences's earnings have been declining at an average annual rate of -61%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually.
Key information
-61.0%
Earnings growth rate
-13.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -86.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How MBX Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -47 | 9 | 42 |
| 31 Mar 24 | 0 | -39 | 8 | 34 |
| 31 Dec 23 | 0 | -33 | 7 | 28 |
Quality Earnings: MBX is currently unprofitable.
Growing Profit Margin: MBX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if MBX's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare MBX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MBX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).
Return on Equity
High ROE: MBX has a negative Return on Equity (-86.65%), as it is currently unprofitable.